Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
A new study shows that so-called “liquid biopsies” may not only sound an early alert that a treatment’s effect is diminishing, but may also help explain why -sometimes offering clues about what to do next.
The benefits of a “Mediterranean diet” (MD) are well-known when it comes to colorectal protection, but it’s hard to know specifically what elements of the diet are the healthiest.
ESMO announced today that the President for 2020-2021 is Professor Solange Peters, MD, PhD, head of the Medical Oncology Service, Chair of Thoracic Oncology, Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
The Impact Factor for Annals of Oncology has risen to 11.855, according to the latest Journal Citation Reports®* (1). The journal now sits 10th in the field, within the top 5% of oncology titles.
Around 3,500 oncology professionals and researchers from around the world will learn about the latest advances in the field at the 19th ESMO World Congress on Gastrointestinal Cancer taking place in Barcelona, Spain, from 28 June to 1 July 2017
ESMO is pleased to announce the ESMO 2019 Annual Congress will take place at the Fira Barcelona, Spain from 27 September to 1 October 2019
The count of submitted abstracts this year has marked a 13% increase since ESMO 2016, with 3,250 abstracts received, 92 of them earmarked for submission as Late Breaking Abstracts...
ESMO welcomes the adoption of the Resolution on Cancer prevention and control in the context of an integrated approach during the 70th World Health Assembly (WHA), May 22 to 31 in Geneva, Switzerland
A late breaking subanalysis of the phase III CONVERT trial to be presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer (SCLC)
White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research to be presented at the European Lung Cancer Conference
The findings pave the way for certain patients to continue treatment if the disease is not progressing according to new, more specific, criteria
Osimertinib improves cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial to be presented at ELCC
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
